AmyriAD to Present Clinical and Preclinical Data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Los Angeles, CA, November 29, 2022 – AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th Clinical Trials on Alzheimer’s Disease Conference (CTAD) on November 29 – December 2 in…

AmyriAD to Host a Key Opinion Leader Webinar on Alzheimer’s Disease Management

-Webinar to discuss investigational strategies to improve symptoms in Alzheimer’s disease patients – Friday, September 30th@ 11:15 a.m. EDT LOS ANGELES, Sept. 19, 2022 (GLOBE NEWSWIRE) — AmyriAD Therapeutics, a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease, today announced that it will host a key opinion leader (KOL)…

Pharma Company AmyriAD Steps into the Light with Phase III Symptom Relief Drug for Alzheimer’s Disease

-After starting up in stealth mode, AmyriAD is ready to debut its Phase 3 investigational drug to relieve Alzheimer’s symptoms. AmyriAD will be attending the Clinical Trials of Alzheimer’s Disease Conference as a Silver Sponsor. – November 10th, 2021 AmyriAD – a biopharmaceutical company led by the development strategist who introduced the cognition enhancing medication…